Clinical features, biomarker profiles, and neuroimaging characteristics in patients from memory clinic in china: The Shanghai Memory Study

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-06-25 DOI:10.1002/alz.70378

Jie Wang, Xiaoxi Ma, Jiaying Lu, Jie Wu, Zhenxu Xiao, Huiwei Zhang, Weiqi Bao, Saineng Ding, Li Zheng, Xiaoniu Liang, Yihui Guan, Chuantao Zuo, Ding Ding, Qianhua Zhao, the Shanghai Memory Study (SMS)

{"title":"Clinical features, biomarker profiles, and neuroimaging characteristics in patients from memory clinic in china: The Shanghai Memory Study","authors":"Jie Wang, Xiaoxi Ma, Jiaying Lu, Jie Wu, Zhenxu Xiao, Huiwei Zhang, Weiqi Bao, Saineng Ding, Li Zheng, Xiaoniu Liang, Yihui Guan, Chuantao Zuo, Ding Ding, Qianhua Zhao, the Shanghai Memory Study (SMS)","doi":"10.1002/alz.70378","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Despite advances in biomarker assessment, molecular neuroimaging, and disease-modifying therapies for cognitive disorders, China lacks well-characterized clinical cohorts integrating comprehensive clinical assessments and multimodal biomarkers.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>The Shanghai Memory Study (SMS), an ongoing hospital-based cohort, enrolled participants undergoing clinical/neuropsychological assessments, genotyping, multimodal imaging, and biospecimen collection.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>From 2012 to 2024, 2001 participants were enrolled: 115 cognitively unimpaired (CU), 938 with mild cognitive impairment (MCI), and 948 with dementia. Positron emission tomography (PET) scan revealed A+/T+ positivity rates of 15.8% in CU, 51.2% in MCI, and 100% in Alzheimer's disease dementia (ADD). Plasma tau phosphorylated at threonine 181 (p-tau181) level increased gradually across the AD continuum. Blood p-tau181 and 18F-Florzolotau PET showed comparable utility for amyloid status identification. In a subcohort of 251 amnestic MCI (aMCI) patients, low Aβ42/Aβ40 and elevated p-tau181 predicted 4.7-year ADD risk.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>By offering an integrated framework, SMS will facilitate the exploration of AD pathogenesis and the understanding of cognitive disorders.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The SMS is an ongoing prospective cohort study based on a memory clinic in China.</li>\n \n <li>The SMS has established a relatively large-scale dataset that includes clinical data, biofluid markers, MRI and PET imaging, and novel biomarkers.</li>\n \n <li>By offering an integrated framework, SMS aims to facilitate the exploration of AD pathogenesis and deepen our understanding of cognitive disorders.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 6","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70378","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70378","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Despite advances in biomarker assessment, molecular neuroimaging, and disease-modifying therapies for cognitive disorders, China lacks well-characterized clinical cohorts integrating comprehensive clinical assessments and multimodal biomarkers.

METHODS

The Shanghai Memory Study (SMS), an ongoing hospital-based cohort, enrolled participants undergoing clinical/neuropsychological assessments, genotyping, multimodal imaging, and biospecimen collection.

RESULTS

From 2012 to 2024, 2001 participants were enrolled: 115 cognitively unimpaired (CU), 938 with mild cognitive impairment (MCI), and 948 with dementia. Positron emission tomography (PET) scan revealed A+/T+ positivity rates of 15.8% in CU, 51.2% in MCI, and 100% in Alzheimer's disease dementia (ADD). Plasma tau phosphorylated at threonine 181 (p-tau181) level increased gradually across the AD continuum. Blood p-tau181 and 18F-Florzolotau PET showed comparable utility for amyloid status identification. In a subcohort of 251 amnestic MCI (aMCI) patients, low Aβ42/Aβ40 and elevated p-tau181 predicted 4.7-year ADD risk.

DISCUSSION

By offering an integrated framework, SMS will facilitate the exploration of AD pathogenesis and the understanding of cognitive disorders.

Highlights

The SMS is an ongoing prospective cohort study based on a memory clinic in China.
The SMS has established a relatively large-scale dataset that includes clinical data, biofluid markers, MRI and PET imaging, and novel biomarkers.
By offering an integrated framework, SMS aims to facilitate the exploration of AD pathogenesis and deepen our understanding of cognitive disorders.

Abstract Image

查看原文本刊更多论文

中国记忆门诊患者的临床特征、生物标志物特征和神经影像学特征：上海记忆研究

尽管在认知障碍的生物标志物评估、分子神经成像和疾病改善疗法方面取得了进展，但中国缺乏整合综合临床评估和多模式生物标志物的具有良好特征的临床队列。方法上海记忆研究（SMS）是一项正在进行的以医院为基础的队列研究，纳入了接受临床/神经心理学评估、基因分型、多模态成像和生物标本收集的参与者。从2012年到2024年，共纳入了2001名参与者：115名认知功能未受损（CU）， 938名轻度认知障碍（MCI）， 948名痴呆症患者。正电子发射断层扫描（PET）显示，CU的A+/T+阳性率为15.8%，MCI为51.2%，阿尔茨海默病痴呆（ADD）为100%。血浆中苏氨酸181磷酸化（p-tau181）水平在AD连续体中逐渐升高。血液p-tau181和18F-Florzolotau PET在淀粉样蛋白状态鉴定方面显示出相当的效用。在251名遗忘性MCI （aMCI）患者的亚队列中，a β42/ a β40低和p-tau181升高可预测4.7年的ADD风险。通过提供一个完整的框架，SMS将促进对AD发病机制的探索和对认知障碍的理解。SMS是一项正在进行的基于中国一家记忆诊所的前瞻性队列研究。SMS已经建立了一个相对较大的数据集，包括临床数据、生物流体标记物、MRI和PET成像以及新型生物标记物。通过提供一个完整的框架，SMS旨在促进对AD发病机制的探索，加深我们对认知障碍的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.